Volume 32, No 3, Mar 2022

ISSN: 1001-0602 
EISSN: 1748-7838 2018 
impact factor 17.848* 
(Clarivate Analytics, 2019)

Volume 32 Issue 3, March 2022: 319-321

LETTERS TO THE EDITOR

Reduced interferon antagonism but similar drug sensitivity in Omicron variant compared to Delta variant of SARS-CoV-2 isolates

Denisa Bojkova¹ , Marek Widera¹ , Sandra Ciesek^1,2,3 , Mark N. Wass^4,* , Martin Michaelis^4,* , Jindrich Cinatl Jr^1,5,*

¹Institute for Medical Virology, University Hospital, Goethe University, Frankfurt am Main, Germany
²German Center for Infection Research, DZIF, External Partner Site Frankfurt am Main, Frankfurt am Main, Germany
³Fraunhofer Institute for Molecular Biology and Applied Ecology (IME), Branch Translational Medicine und Pharmacology, Frankfurt am Main, Germany
⁴School of Biosciences, University of Kent, Canterbury, UK
⁵Dr. Petra Joh-Forschungshaus, Frankfurt am Main, Germany
Correspondence: Mark N. Wass(M.N.Wass@kent.ac.uk)Martin Michaelis(M.Michaelis@kent.ac.uk)Jindrich Cinatl Jr(Cinatl@em.uni-frankfurt.de)

Dear Editor,

Omicron (B.1.1.529), is a heavily mutated and highly contagious SARS-CoV-2 variant, which is currently causing large outbreaks in many countries. Protection provided by current vaccines is substantially reduced against Omicron.1,2 Moreover, many immunocompromised individuals cannot effectively be protected by vaccines.3 Hence, antiviral therapies will be essential to protect the most vulnerable individuals from severe COVID-19.

https://doi.org/10.1038/s41422-022-00619-9

FULL TEXT | PDF

Browse 460